An observational study in Benign or Malignant Liver and Bile Duct Disease, sponsored by Methodist Health System. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Methodist Health System · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Bile Duct Diseases with a site in United States — 2 open to participants now, 4 under way, none of them phase 3. Bile Duct Diseases · United States.
Among the 22 studies in Bile Duct Diseases with a site in United States, this one is one of 2 that started in 2023, is one of 9 observational ones, and was the 10th registered.
50 studies on the registry are indexed under Bile Duct Diseases; 13 are open to participants now.
Browse Bile Duct Diseases studies →2 of the 22 studies in Bile Duct Diseases with a site in United States are open now. Recruiting first, the newest first:
Orlando Health, Inc. · Sites in United States
Ages 18–100
Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Bile Duct Diseases studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 126 is below the median of 166 across 18 observational studies indexed under Bile Duct Diseases.
Median enrollment 46 across the 12 interventional studies, 50 across the 9 observational. Of the 15 that completed or were terminated, 10 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 22 have an industry lead sponsor. The 10 most frequent:
Methodist Health System is the lead sponsor of 170 studies on the registry; 50 are open to participants now.
Methodist Health System has 2 studies filed under Bile Duct Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Bile Duct Diseases with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04637243Methodist Health SystemOutcomes From Treatment Liver and Bile Duct Diseases | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Bile Duct Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
It is reported in the literature that the treatment of any liver and bile duct disease process, whether benign or malignant, continues to be a huge challenge. For example, patients with adenocarcinoma continue to be diagnosed at an advanced stage with medical and surgical options that are improving in terms of outcome measurements but with much more room for improvement. Our goal is to continue to review our treatment outcomes to further improve overall survival, overall symptom control, mortality and morbidity.
The main aim of this study is to evaluate and compare the outcomes from our multiple treatments of benign or malignant liver and bile duct diseases.
The study will be a retrospective chart review of patients who have been diagnosed with benign or malignant liver and bile duct disease under the practices of Rohan Jeyarajah, M.D., Houssam Osman, M.D., F.A.C.S., Edward Cho, M.D., Sc.M at Methodist Health System Hospital in Richardson, T.X. We plan to conduct an analysis of patients meeting the inclusion criteria form 2005 to present (up to the day before this study receives IRB approval). Charts will also be reviewed by the PI. Sub-I, Fellows, Office Staff, Clinical Research Coordinator who are delegated to do so by the PI. Data will be obtained from a national database. Data will be analyzed primarily by the study conductors.
patients who have been diagnosed with benign or malignant liver and bile duct disease under the practices of Rohan Jeyarajah, M.D., Houssam Osman, M.D., F.A.C.S., Edward Cho, M.D., Sc.M at Methodist Health System Hospital in Richardson, T.X.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Available treatment of Benign or Malignant Liver and Bile Duct Diseases
Mortality from Treatment of Benign or Malignant Liver and Bile Duct Diseases
Mortality
Time frame: 2005 to 2019
Morbidity from Treatment of Benign or Malignant Liver and Bile Duct Diseases
Morbidity
Time frame: 2005 to 2019
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2023 (actual). Primary completion is estimated for Dec 2026, 45 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.